

**Recommendations from York and Scarborough Medicines Commissioning Committee September 17 2014 – Vale of York CCG**

<b>Drug and Brand name</b>	<b>Indication</b>	<b>Recommendation</b>	<b>Place in therapy</b>	<b>RAG status</b>	<b>Potential full year cost impact</b>
Loperamide (generic) <i>tablets</i>	High volume output from a stoma	Approved	Patients with a stoma should be given the tablet formulation <i>rather than capsules</i> when indicated to reduce stoma output	Green	Price difference +26p for 30 tablets for this small cohort of patients
Avanafil (Spedra®)	Erectile dysfunction in adult men	Approved	Sildenafil is the 1 <sup>st</sup> line PDE-5 inhibitor, avanafil is commissioned as a 3 <sup>rd</sup> line option (after vardenafil which is 2 <sup>nd</sup> line)	Green	Savings could be achieved if prescribed instead of tadalafil formulations.
Certolizumab (Cimzia®)	Psoriatic arthritis	Approved	As an option for the management of psoriatic arthritis in line with NICE TA 199	Red	Savings may be achieved in year 1 due to a patient access scheme. Beyond year one costs comparable with other subcutaneous anti-TNFs
Ciclosporin topical (drops/ointment)	Ocular inflammatory disorders when topical steroids are not tolerated or ineffective	Approved	Drops or ointment as a second line option made available for specialist use	Red	No drug cost impact on the CCG.
Leuprorelin (Prostap formulations)	Prostate cancer	Approved	Formulary reclassification, leuprorelin acetate is a formulary gonadorelin (LHRH) analogue. The agent with the lowest acquisition/administration cost should be chosen.	Amber-specialist recommendation	In practice, this agent is already prescribed in GP practices.

<b>Drug and Brand name</b>	<b>Indication</b>	<b>Recommendation</b>	<b>Place in therapy</b>	<b>RAG status</b>	<b>Potential full year cost impact</b>
Fluorouracil 0.5% and salicylic acid cutaneous solution (Actikerall®)	Actinic keratosis	Approved	As part of treatment options in actinic keratosis primary care treatment pathway	Green	2nd most cost effective treatment within the pathway
Ingenol mebutate gel (Picato®)	Actinic keratosis	Approved	As part of treatment options in actinic keratosis primary care treatment pathway	Green	Restricted as less cost effective than topical fluorouracil
Lubiprostone (Amitiza®)	Chronic idiopathic constipation	Approved as per NICE TA 318	Gastroenterology consultant initiation in line with NICE TA 318. GPs may continue the prescribing when a review after 2 weeks therapy demonstrates benefit.	Amber – no shared care	Current spend on comparator agent (prucalopride) is £13,000.
Prasugrel (Efient®)	Percutaneous coronary intervention for treating acute coronary syndromes	Approved as per NICE TA 317	This is a review of TA 182 therefore prasugrel will already be an option on local formularies	Amber – no shared care	Significant financial impact is not expected
Lurasidone (Latuda®)	Schizophrenia in adults	Not approved	Leeds and York Partnership mental health NHS Trust have not approved this treatment	Black	No cost impact